Appclon and Chong Kun Dang to Jointly Develop Bispecific Antibody Therapies for Refractory Cancers
Discovery of Next-Generation Immuno-Oncology Drugs
for Refractory Diseases Including Solid Tumors
Appclon, a company specializing in the development of antibody-based new drugs, announced on March 30 that it is actively proceeding with a joint research and development project with Chong Kun Dang to create next-generation bispecific antibodies using its proprietary AffiMab platform.
The goal of this collaboration is to combine the core competencies of both companies to develop innovative bispecific antibody drugs for patients suffering from refractory cancers with high unmet medical needs. In particular, the two companies have agreed to pursue a flexible and comprehensive research strategy aimed at discovering pipeline candidates from multiple perspectives during this joint project.
The AffiMab-based bispecific antibody platform owned by Appclon is designed to selectively activate immune cells only at specific sites where cancer, such as in the tumor microenvironment (TME), is present. This mechanism offers the advantage of maximizing therapeutic efficacy while minimizing the risk of systemic toxic side effects typically associated with existing immuno-oncology drugs.
In May last year, Chong Kun Dang participated in a third-party paid-in capital increase for Appclon worth 12.2 billion won, becoming the second-largest shareholder with a 7.33% stake based on single shareholder standards. Following this investment, Chong Kun Dang secured the domestic exclusive priority sales rights for Appclon's blood cancer CAR-T cell therapy "Nespacell (AT101)" and established a "Joint Development Committee" composed of experts to initiate joint development in the bispecific antibody field. The development of this bispecific antibody drug candidate is a key project derived from in-depth discussions within the committee.
A representative from Chong Kun Dang stated, "Appclon's AffiMab is a next-generation T-cell engager platform with outstanding target expandability. By integrating it with Chong Kun Dang's antibody new drug pipeline, we believe it can provide new treatment alternatives for various cancer types. As the second-largest shareholder, we will go beyond financial investment and actively leverage Chong Kun Dang's extensive global new drug development capabilities and clinical expertise to develop innovative next-generation anticancer drugs."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Jongseo, CEO of Appclon, emphasized, "Since last year's strategic equity investment, the two companies have deeply shared their visions and technological capabilities. By maximizing the potential of T-cell engager bispecific antibodies utilizing the AffiMab platform, we will achieve innovative outcomes that lead the global biotech market together with Chong Kun Dang."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.